Resources

Client Alerts, News Articles, Blog Posts, & Multimedia

Everything you need to know about BMD and the industry.

Explosive Growth in Pot of Gold Opportunity for Bank (and Other) Cannabis Lenders Driving Erosion of the Barriers

Client Alert, Blog Post

Our original article on bank lending to the cannabis industry anticipated that the convergence of interest between banks and the cannabis industry would draw more and larger banks to the industry. Banks were awash in liquidity with limited deployment options, while bankable cannabis businesses had rapidly growing needs for more and lower cost credit. 

Since then, the pot of gold opportunity for banks to lend into the cannabis industry has grown exponentially due to a combination of market constraints on equity causing a dramatic shift to debt and the ever-increasing capital needs of one of the country’s fastest growing industries. At the same time, hurdles to entry of new banks are being systematically cleared as the yellow brick road to the cannabis industry’s access to the financial markets is being paved, brick by brick, by the progressively increasing number and size of banks that are now entering the market. 

Due to these circumstances, and the developments described below, this is driving the emergence of (i) a largely one off, deal by deal participation market, (ii) a nascent syndication opportunity, and (iii) a “politics makes strange bedfellows” coalescence of co-lending by banks with funds and, perhaps, credit unions. Addressing these developments, we have initiated an effort to create an informal community of institutional cannabis lenders to facilitate co-lending and participations, as well as to provide an opportunity to stay abreast of rapidly evolving best practices. We have already received indications of interests from several banks, syndicators and funds, including billion $ plus Chicago Atlantic. Banks, credit unions, cannabis funds and family office lenders that are in or interested in the cannabis market, and may wish to participate, should contact us directly at salenn@bmdllc.com. 

Consistent with expectations expressed in the bank lending article and subsequent blogs and conference presentations, even without any federal enabling legislation we’ve seen that happening. Shortly after the article, Harborside announced what may have been the first significant loan to a cannabis company from a substantial commercial bank. More recently, as reflected in our most recent blog, Fluresh Cannabis, a substantial Michigan based cannabis company, announced it had closed on an almost $50 million in loans from a commercial bank. Interestingly, even though those loans were not one offs for these banks, neither wants to be identified.

The growth in the opportunity is reflected in many recent articles, including two in MJBiz. On April 28, 2022, Finance Reporter Nick Thomas noted that “Debt will… increasingly be an option for well-run cannabis companies that are nearing profitability.” 

A day later, Veridian Capital Advisors, an authoritative source of information, data and analysis, elaborated on the shift to debt solutions by public companies and large multi-state operators, explaining: 

Public companies are loathe to raise equity for two reasons:

  • Prices are well below perceived intrinsic values.
  • Hope for legalization reform that could enable uplisting is freezing the market.

If you expect that you might be able to raise capital on the Nasdaq exchange next year, why would you do it now?

Major multistate operators can raise debt at rates of less than 10% (before fees), and it is a much cheaper source of capital than equity. 

Clearly, they are correct, but the time has come to add the increasingly available lower cost bank financing into the equation. For one thing, the reduction in rates cited by Veridian is, at least in part, influenced by the rate pressure resulting from banks that are lending to the “A” and “B+” credits in the industry (an increasing universe) in the 6-7% range (sometimes lower). For another, the perspective they express is likely applicable to the smaller MSOs and single state operators that have made it through the eye of the needle, generating revenues and profits, that now need capital for expansion they are considering, either organic or via acquisitions. 

If so, this would be both good and bad news for those operators. 

  • The bad is that big declines in prices of public companies can have a negative ripple effect on the equity markets in general and the successful smaller, private operators in particular. While some of the money now going into the public markets may shift focus to those operators, the theoretical increase in the pool of equity capital available may be more than offset by the caution with which it is deployed.
  • The good is that the factors driving the declines in the cost of debt noted by Veridian, also underly the steadily increasing sources and availability of debt capital to the successful smaller operator at more favorable pricing. Keep your eye on the banks progressively opening up to the cannabis industry, which appear to be finding attractive the smaller, successful operators with assets and doing business in geographic markets with which they are familiar. 

However, the ability of the banking industry to meet the industry’s growing appetite for credit is currently constrained by the size of the banks that have taken the plunge. The Fluersh loan blog commented on the significance of a $50 million commercial bank loan to Michigan based Fluresh Cannabis. While the bank has not been identified, it is representative of the evolution of banks lending to the cannabis industry from the initial players—the pioneering small community banks that were the early entrants—into banks with assets of more than $50 billion. 

Without going into detail, the size of loans that a bank can make are, to a large extent, correlated to its size. The larger banks now making loans, like the one to Fluresh, are or will soon be running up against either regulatory or house limits on loans to one borrower or industry concentrations. This is a particularly acute challenge where the borrower is growing and will need follow on financing. 

One of the results has been to create a need for participating portions of loans to other banks or cannabis lenders. Perhaps most significant at the moment has been the above referenced nascent combination of bank and fund or other institutional lenders acting as co-lenders in transactions with customized structures, generally reserving to the bank deposit relationships and sometimes providing it with “first out” rights. 

Returning to the thrust of this blog and the recurrent thread of our articles, blogs and presentations—“follow the money and out of the shadows, into the mainstream,” this expanding need for debt, combined with the rapid movement of the cannabis industry out of the shadows, is almost certain to begin to progressively attract the next tiers of banks, perhaps those between $50-200 billion, banks whose higher loan limits could well have a significant impact on cannabis businesses and the cannabis debt markets. 

For questions, please contact Business and Corporate Law Member and Managing Partner of BMD’s Phoenix/Scottsdale location Stephen Lenn at salenn@bmdllc.com, or 480.687.9747.


Asian American & Pacific Islander Heritage Month Employee Spotlight | Jessica Hew

In honor of Asian American & Pacific Islander Heritage Month, and as part of BMD’s ongoing diversity and inclusion efforts, we are featuring BMD Senior Counsel Member Jessica Hew in an employee spotlight.

Telehealth Flexibility Updates: HIPAA, DEA, and CMS

The Covid-19 Public Health Emergency (PHE) officially ended on May 11, 2023. But what does that mean for telehealth, a field that expanded exponentially during the PHE? Fortunately, many of the flexibilities will remain intact, at least temporarily. This client alert presents a brief overview of the timelines that providers need to follow, but for a more comprehensive review of telehealth flexibilities and when they will end

WEBINAR SERIES RECAP | Ending the Public Health Emergency + Post-Pandemic Check-Up

Some may take the position that the rest of the country already returned to a new “normal” following the COVID-19 pandemic.  But healthcare providers continue to implement COVID protocols and navigate the ever-changing healthcare regulations at both the federal and state levels.  It is important for healthcare providers to take time for a “Healthcare Check-Up” with the start of 2023 and the ending of the Public Health Emergency (“PHE”).

Sharp Rise in False Claims Act Cases - Navigating the FCA Waters

Recently, on April 18, 2023, the United States Supreme Court heard arguments regarding the FCA’s scienter, or mental state, requirement. To prove violation of the FCA, the statute requires that a defendant “knowingly” file false claims for payment. The term “knowingly” is defined within the statute to mean a person that acts with actual knowledge, deliberate ignorance, or reckless disregard. Circuit courts are split on how to interpret and apply the knowledge element of the FCA, and based on the Supreme Court’s decision, there will be a large impact on healthcare defendants and their businesses as well as anyone who contracts with, or receives money from, a federal program. A broader interpretation of the FCA would unnecessarily target and stifle healthcare, and other businesses, for simple errors in daily operations. This goes against the intended application of the FCA, which was to prevent fraudulent activity.

Areas of Opportunity in Columbus: Highlights from the Columbus Opportunity Summit

On April 27, 2023 Columbus Business First held its annual Columbus Opportunity Summit, bringing together business and economic development leaders to provide an update on how Central Ohio is preparing for expected growth in the coming years, an issue heightened by the arrival of Intel at its 1,000 acre site in Licking County, just outside of Columbus. The site will be home to two new chip factories with room to grow to a total of eight factories and is a $20 Billion investment.